Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laura Helbling

Laura Helbling is Director of Research at Prevision Policy and a Senior Writer at The RPM Report (now Pink Sheet). Laura has a degree in magazine journalism from the University of Missouri School of Journalism.

Latest From Laura Helbling

A Final Push For US Hepatitis C Eradication Plan In 2024

The Biden Administration is hoping that it can attach funding for a national hepatitis C ‘subscription’ program into the delayed fiscal 2024 appropriations bills.

Reimbursement Legislation

Menopausal Status Is Another Focus For US FDA Trial Inclusion Efforts

US FDA is emphasizing the need to assess the effects of menopause on drug safety and efficacy as a continuation of the agency’s efforts to encourage clinical trial sponsors to look more systematically for differences in clinical trial subpopulations.

Diversity & Inclusion Clinical Trials

Gene Therapy Cost Effectiveness: US ICER Supports Million-Dollar Prices

Institute for Clinical and Economic Review continues to assign high values to novel gene therapies, suggesting that Orchard’s pending ‘arsa-cel’ for MLD could be cost effective at a price as high as $4 million per treatment.

Gene Therapy Reimbursement

Antibiotic Payment Incentives: Advocates Still Looking For More

After some success in enacting new regulatory and exclusivity incentives in the US over the past decade, antibiotic research advocates are urging action on the payment/reimbursement side. One start-up CEO argues that Medicare needs to rethink its approach to payment for hospital antibiotics.

Infectious Diseases Reimbursement

Diversity Plans For US FDA: Oncology Experience Will Inform New Policies

US FDA will be transitioning from the ‘diversity plans’ outlined in recent guidance to the new, legislatively directed ‘diversity action plans’ by the end of 2023. The oncology group is leading the way in gathering early perspectives on industry approaches.

Diversity & Inclusion Guidance Documents

US FDA Outlines Psychedelic Drug Trial Principles, But It Won’t Be An Easy Trip

The US FDA is offering its first formal advice for potential approaches to develop psychedelic drugs for therapeutic indications. But it won’t be easy.

Neurology Guidance Documents
See All
UsernamePublicRestriction

Register